Mathematical models of the epidemiology and control of drug-resistant TB

Expert Review of Respiratory Medicine

Volumn 3, Issue 1, 2009, Pages 67-79

  Cohen, Ted ^a,b   Dye, Christopher ^c   Colijn, Caroline ^d   Williams, Brian ^c   Murray, Megan ^a,b,e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Antibiotic resistance; Extensively drug resistant; Mathematical model; Multidrug resistant; TB

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; COMORBIDITY; DRUG EFFICACY; EPIDEMIOLOGICAL DATA; HEALTH CARE POLICY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; INDIVIDUALIZATION; LUNG TUBERCULOSIS; MATHEMATICAL MODEL; MEDICAL RESEARCH; MULTIDRUG RESISTANCE; PATIENT CARE; PATIENT COMPLIANCE; PREVALENCE; REVIEW; SHORT COURSE THERAPY; SOUTH AFRICA; TUBERCULOSIS CONTROL;

EID: 67849122589     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.3.1.67     Document Type: Review

References (123)

1. WHO. Global tuberculosis control - surveillance, planning, financing. Geneva, Switzerland. WHO/HTM/TB/2008.393 (2008).
2. World Health Organization. Anti-tuberculosis drug resistance in the world report no. 4. Geneva, Switzerland. WHO/HTM/TB/2008.394 (2008).
3. Gandhi NR, Moll A, Sturm AW et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368(9547), 1575-1580 (2006).
4. Gillespie S. Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective. Antimicrob. Agents Chemother. 46(2), 267-274 (2002).
5. David HL. Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl. Microbiol. 20(5), 810-814 (1970).
6. Shah NS, Wright A, Bai G-H 6 et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg. Infect. Dis. 13(3), 380-387 (2007).
7. Vynnycky E, Fine PE. The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection. Epidemiol. Infect. 119(2), 183-201 (1997).
8. Blower SM, McLean AR, Porco TC et al. The intrinsic transmission dynamics of tuberculosis epidemics. Nat. Med. 1(8), 815-821 (1995).
9. Blower SM, Small PM, Hopewell PC. Control strategies for tuberculosis epidemics: new models for old problems. Science 273(5274), 497-500 (1996).
10. Dye C, Garnett GP, Sleeman K, Williams BG. Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Directly observed short-course therapy. Lancet 352(9144), 1886-1891 (1998).
11. Murray CJ, Salomon JA. Modeling the impact of global tuberculosis control strategies. Proc. Natl Acad. Sci. USA 95(23), 13881-13886 (1998).
12. Lew W, Pai M, Oxlade O, Martin D, Menzies D. Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis. Ann. Intern. Med. 149(2), 123-134 (2008).
13. Espinal MA, Kim SJ, Suarez PG 13 et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 283(19), 2537-2545 (2000).
14. Lipsitch M, Levin BR. Population dynamics of tuberculosis treatment: mathematical models of the roles of non-compliance and bacterial heterogeneity in the evolution of drug resistance. Int. J. Tuberc. Lung Dis. 2(3), 187-199 (1998).
15. Dye C, Espinal MA. Will tuberculosis become resistant to all antibiotics? Proc. Biol. Sci. 268(1462), 45-52 (2001).
16. Danilchanka O, Mailaender C, Niederweis M. Identification of a novel multidrug efflux pump of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 52(7), 2503-2511 (2008).
17. Boshoff HIM, Reed MB, Barry CE, Mizrahi V. DNAE2 polymerase contributes to in vivo survival and the emergence of drug resistance in Mycobacterium tuberculosis. Cell 113(2), 183-193 (2003).
18. Glynn JR, Whiteley J, Bifani PJ, Kremer K, van Soolingen D. Worldwide occurrence of Beijing/W strains of Mycobacterium tuberculosis: a systematic review. Emerg. Infect. Dis. 8(8), 843-849 (2002).
19. Cox HS, Kubica T, Doshetov D, Kebede Y, Rüsch-Gerdess S, Niemann S. The Beijing genotype and drug resistant tuberculosis in the Aral Sea region of Central Asia. Respir. Res. 6, 134 (2005).
20. Sun YJ, Lee ASG, Wong SY 20 et al. Genotype and phenotype relationships and transmission analysis of drug-resistant tuberculosis in Singapore. Int. J. Tuberc. Lung Dis. 11(4), 436-442 (2007).
21. Almeida D, Rodrigues C, Ashavaid TF, Lalvani A, Udwadia ZF, Mehta A. High incidence of the Beijing genotype among multidrug-resistant isolates of Mycobacterium tuberculosis in a tertiary care center in Mumbai, India. Clin. Infect. Dis. 40(6), 881-886 (2005).
22. Alavez-Ramírez J, Castellanos JR, Esteva L et al. Within-host population dynamics of antibiotic-resistant M. tuberculosis. Math. Med. Biol. 24(1), 35-56 (2007).
23. Kirschner D. Dynamics of co-infection with M. tuberculosis and HIV-1. Theor. Popul. Biol. 55(1), 94-109 (1999).
24. Demissie M, Lemma E, Gebeyehu M, Lindtjorn B. Sensitivity to anti-tuberculosis drugs in HIV-positive and -negative patients in Addis Ababa. Scand. J. Infect. Dis. 33(12), 914-919 (2001).
25. Espinal MA, Laserson K, Camacho M et al. Determinants of drug-resistant tuberculosis: analysis of 11 countries. Int. J. Tuberc. Lung Dis. 5(10), 887-893 (2001).
26. Dye C, Williams BG, Espinal MA, Raviglione MC. Erasing the world's slow stain: strategies to beat multidrug-resistant tuberculosis. Science 295(5562), 2042-2046 (2002).
27. Peloquin CA, Nitta AT, Burman WJ et al. Low antituberculosis drug concentrations in patients with AIDS. Ann. Pharmacother. 30(9), 919-925 (1996).
28. Tappero JW, Bradford WZ, Agerton TB et al. Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana. Clin. Infect. Dis. 41(4), 461-469 (2005).
29. Weiner M, Benator D, Burman W et al. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin. Infect. Dis. 40(10), 1481-1491 (2005).
30. Blower SM, Gerberding JL. Understanding, predicting and controlling the emergence of drug-resistant tuberculosis: a theoretical framework. J. Mol. Med. 76(9), 624-636 (1998).
31. Dye C, Williams BG. Criteria for the control of drug-resistant tuberculosis. Proc. Natl Acad. Sci. USA 297(14), 8180-8185 (2000).
32. Castillo-Chavez C, Feng Z. To treat or not to treat: the case of tuberculosis. J. Math. Biol. 35(6), 629-656 (1997).
33. Middlebrook G, Cohn ML. Some observations on the pathogenicity of isoniazid-resistant variants of tubercle bacilli. Science 118(3063), 297-299 (1953).
34. Davies AP, Billington OJ, Bannister BA, Weir WR, McHugh TD, Gillespie SH. Comparison of fitness of two isolates of Mycobacterium tuberculosis, one of which had developed multi-drug resistance during the course of treatment. J. Infect. 41(2), 184-187 (2000).
35. Cohen T, Murray M. Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness. Nat. Med. 10(10), 1117-1121 (2004).
36. Blower S, Chou T. Modeling the emergence of the 'hot zones': tuberculosis and the amplification dynamics of drug resistance. Nat. Med. 10(10), 1111-1116 (2004).
37. van Soolingen D, de Haas PE, van Doorn HR, Kuijper E, Rinder H, Borgdorff MW. Mutations at amino acid position 315 of the katG gene are associated with high-level resistance to isoniazid, other drug resistance, and successful transmission of Mycobacterium tuberculosis in the Netherlands. J. Infect. Dis. 182(6), 1788-1790 (2000).
38. Gagneux S, Long CD, Small PM, Van T, Schoolnik GK, Bohannan BJM. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 312(5782), 1944-1946 (2006).
39. Gagneux S, Burgos MV, DeRiemer K et al. Impact of bacterial genetics on the transmission of isoniazid-resistant Mycobacterium tuberculosis. PLoS Pathog. 2(6), E61 (2006).
40. Pym AS, Saint-Joanis B, Cole ST. Effect of katG mutations on the virulence of Mycobacterium tuberculosis and the implication for transmission in humans. Infect. Immun. 70(9), 4955-4960 (2002).
41. Cohen T, Sommers B, Murray M. The effect of drug resistance on the fitness of Mycobacterium tuberculosis. Lancet Infect. Dis. 3(1), 13-21 (2003).
42. Andersson DI, Levin BR. The biological cost of antibiotic resistance. Curr. Opin. Microbiol. 2(5), 489-493 (1999).
43. DeRiemer K, García-García L, Bobadilla-del-Valle M et al. Does DOTS work in populations with drug-resistant tuberculosis? Lancet 365(9466), 1239-1245 (2005).
44. Huong NT, Lan NTN, Cobelens FGJ et al. Antituberculosis drug resistance in the south of Vietnam: prevalence and trends. J. Infect. Dis. 194(9), 1226-1232 (2006).
45. Wallinga J, Teunis P. Different epidemic curves for severe acute respiratory syndrome reveal similar impacts of control measures. Am. J. Epidemiol. 160(6), 509-516 (2004).
46. White LF, Pagano M. A likelihood-based method for real-time estimation of the serial interval and reproductive number of an epidemic. Stat. Med. 27(16), 2999-3016 (2008).
47. Vynnycky E, Fine PE. The long-term dynamics of tuberculosis and other diseases with long serial intervals: implications of and for changing reproduction numbers. Epidemiol. Infect. 121(2), 309-324 (1998).
48. Murray M, Alland D. Methodological problems in the molecular epidemiology of tuberculosis. Am. J. Epidemiol. 155(6), 565-571 (2002).
49. Murray M. Sampling bias in the molecular epidemiology of tuberculosis. Emerg. Infect. Dis. 8(4), 363-369 (2002).
50. Glynn JR, Vynnycky E, Fine PE. Influence of sampling on estimates of clustering and recent transmission of Mycobacterium tuberculosis derived from DNA fingerprinting techniques. Am. J. Epidemiol. 149(4), 366-371 (1999).
51. Laserson KF, Osorio L, Sheppard JD et al. Clinical and programmatic mismanagement rather than community outbreak as the cause of chronic, drugresistant tuberculosis in Buenaventura, Colombia, 1998. Int. J. Tuberc. Lung Dis. 4(7), 673-683 (2000).
52. Cohen T, Colijn C, Finklea B et al. Are survey-based estimates of the burden of drug resistant TB too low? Insight from a simulation study. PLoS ONE 3(6), E2363 (2008).
53. Wells CD, Cegielski JP, Nelson LJ et al. HIV infection and multidrug-resistant tuberculosis: the perfect storm. J. Infect. Dis. 196(Suppl. 1), S86-S107 (2007).
54. Corbett EL, Watt CJ, Walker N et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch. Intern. Med. 163(9), 1009-1021 (2003).
55. Ben Amor Y, Nemser B, Singh A, Sankin A, Schluger. Underreported threat of multidrug-resistant tuberculosis in Africa. Emerg. Infect. Dis. 14(9), 1345-1352 (2008).
56. Currie CSM, Williams BG, Cheng RCH, Dye C. Tuberculosis epidemics driven by HIV: is prevention better than cure? AIDS 17(17), 2501-2508 (2003).
57. Dowdy DW, Chaisson RE, Moulton LH, Dorman SE. The potential impact of enhanced diagnostic techniques for tuberculosis driven by HIV: a mathematical model. AIDS 20(5), 751-762 (2006).
58. Porco TC, Small PM, Blower SM. Amplification dynamics: predicting the effect of HIV on tuberculosis outbreaks. J. Acquir. Immune Defic. Syndr. 28(5), 437-444 (2001).
59. Sharomi O, Podder CN, Gumel AB, Song B. Mathematical analysis of the transmission dynamics of HIV/TB coinfection in the presence of treatment. Math. Biosci. Eng. 5(1), 145-174 (2008).
60. Williams BG, Granich R, Chauhan LS, Dharmshaktu NS, Dye C. The impact of HIV/AIDS on the control of tuberculosis in India. Proc. Natl Acad. Sci. USA 102(27), 9619-9624 (2005).
61. Bacaër N, Ouifki R, Pretorius C, Wood R, Williams B. Modeling the joint epidemics of TB and HIV in a South African township. J. Math. Biol. 57(4), 557-593 (2008).
62. Narvskaya O, Otten T, Limeschenko E et al. Nosocomial outbreak of multidrugresistant tuberculosis caused by a strain of Mycobacterium tuberculosis W-Beijing family in St. Petersburg, Russia. Eur. J. Clin. Microbiol. Infect. Dis. 21(8), 596-602 (2002).
63. Moro ML, Gori A, Errante I et al. An outbreak of multidrug-resistant tuberculosis involving HIV-infected patients of two hospitals in Milan, Italy. Italian Multidrug-Resistant Tuberculosis Outbreak Study Group. AIDS 12(9), 1095-1102 (1998).
64. Ritacco V, Lonardo MD, Reniero A et al. Nosocomial spread of human immunodeficiency virus-related multidrugresistant tuberculosis in Buenos Aires. J. Infect. Dis. 176(3), 637-642 (1997).
65. Kenyon TA, Ridzon R, Luskin-Hawk R et al. A nosocomial outbreak of multidrugresistant tuberculosis. Ann. Intern. Med. 127(1), 32-36 (1997).
66. Edlin BR, Tokars JI, Grieco MH et al. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N. Engl. J. Med. 326(23), 1514-1521 (1992).
67. Beck-Sagué C, Dooley SW, Hutton MD et al. Hospital outbreak of multidrugresistant Mycobacterium tuberculosis infections. Factors in transmission to staff and HIV-infected patients. JAMA 268(10), 1280-1286 (1992).
68. Basu S, Andrews JR, Poolman EM et al. Prevention of nosocomial transmission of extensively drug-resistant tuberculosis in rural South African district hospitals: an epidemiological modelling study. Lancet 370(9597), 1500-1507 (2007).
69. Oeltmann JE, Varma JK, Ortega L et al. Multidrug-resistant tuberculosis outbreak among US-bound Hmong refugees, Thailand, 2005. Emerg. Infect. Dis. 14(11), 1715-1721 (2008).
70. Mathema B, Kurepina NE, Bifani PJ, Kreiswirth BN. Molecular epidemiology of tuberculosis: current insights. Clin. Microbiol. Rev. 19(4), 658-685 (2006).
71. Gagneux S, DeRiemer K, Van T et al. Variable host-pathogen compatibility in Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA 103(8), 2869-2873 (2006).
72. Baker L, Brown T, Maiden MC, Drobniewski F. Silent nucleotide polymorphisms and a phylogeny for Mycobacterium tuberculosis. Emerg. Infect. Dis. 10(9), 1568-1577 (2004).
73. Brosch R, Gordon SV, Marmiesse M et al. A new evolutionary scenario for the Mycobacterium tuberculosis complex. Proc. Natl Acad. Sci. USA 99(6), 3684-3689 (2002).
74. Filliol I, Motiwala AS, Cavatore M et al. Global phylogeny of Mycobacterium tuberculosis based on single nucleotide polymorphism (SNP) analysis: insights into tuberculosis evolution, phylogenetic accuracy of other DNA fingerprinting systems, and recommendations for a minimal standard SNP set. J. Bacteriol. 188(2), 759-772 (2006).
75. Thwaites G, Caws M, Chau TTH et al. The relationship between Mycobacterium tuberculosis genotype and the clinical phenotype of pulmonary and meningeal tuberculosis. J. Clin. Microbiol. 46(4), 1363-1368 (2008).
76. López B, Aguilar D, Orozco H et al. A marked difference in pathogenesis and immune response induced by different Mycobacterium tuberculosis genotypes. Clin. Exp. Immunol. 133(1), 30-37 (2003).
77. Valway SE, Sanchez MP, Shinnick TF et al. An outbreak involving extensive transmission of a virulent strain of Mycobacterium tuberculosis. N. Engl. J. Med. 338(10), 633-639 (1998).
78. Hanekom M, van der Spuy GD, Streicher E et al. A recently evolved sublineage of the Mycobacterium tuberculosis Beijing strain family is associated with an increased ability to spread and cause disease. J. Clin. Microbiol. 45(5), 1483-1490 (2007).
79. Gagneux S, Small PM. Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development. Lancet Infect. Dis. 7(5), 328-337 (2007).
80. Hanekom M, van der Spuy GD, van Pittius NCG et al. Evidence that the spread of Mycobacterium tuberculosis strains with the Beijing genotype is human population dependent. J. Clin. Microbiol. 45(7), 2263-2266 (2007).
81. Mendelson M, Walters S, Smith I, Kaplan G. Strain-specific mycobacterial lipids and the stimulation of protective immunity to tuberculosis. Tuberculosis (Edinb.) 85(5-6), 407-413 (2005).
82. Reed MB, Domenech P, Manca C et al. A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response. Nature 431(7004), 84-87 (2004).
83. Pheiffer C, Betts JC, Flynn HR, Lukey PT, van Helden P. Protein expression by a Beijing strain differs from that of another clinical isolate and Mycobacterium tuberculosis H37Rv. Microbiology 151(Pt 4), 1139-1150 (2005).
84. Dormans J, Burger M, Aguilar D et al. Correlation of virulence, lung pathology, bacterial load and delayed type hypersensitivity responses after infection with different Mycobacterium tuberculosis genotypes in a BALB/c mouse model. Clin. Exp. Immunol. 137(3), 460-468 (2004).
85. Rindi L, Peroni I, Lari N, Bonanni D, Tortoli E, Garzelli C. Variation of the expression of Mycobacterium tuberculosis ppe44 gene among clinical isolates. FEMS Immunol. Med. Microbiol. 51(2), 381-387 (2007).
86. Rodrigues P, Gomes MGM, Rebelo C. Drug resistance in tuberculosis - a reinfection model. Theor. Popul. Biol. 71(2), 196-212 (2007).
87. Colijn C, Cohen T, Murray M. Latent coinfection and the maintenance of strain diversity. Bull. Math. Biol. 71(1), 247-263 (2009).
88. Feng Z, Iannelli M, Milner F. A two-strain TB model with age-structure. SIAM J. Appl. Math. 62 (5), 1634-1656 (2002).
89. Raviglione MC, Uplekar MW. WHO's new Stop TB Strategy. Lancet 367(9514), 952-955 (2006).
90. Han LL, Sloutsky A, Canales R et al. Acquisition of drug resistance in multidrug-resistant Mycobacterium tuberculosis during directly observed empiric retreatment with standardized regimens. Int. J. Tuberc. Lung Dis. 9(7), 818-821 (2005).
91. Sterling TR, Lehmann HP, Frieden TR. Impact of DOTS compared with DOTSplus on multidrug resistant tuberculosis and tuberculosis deaths: decision analysis. BMJ 326(7389), 574 (2003).
92. Pillay M, Sturm AW. Evolution of the extensively drug-resistant F15/LAM4/ KZN strain of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa. Clin. Infect. Dis. 45(11), 1409-1414 (2007).
93. World Health Organization. The Stop TB Strategy: building on and enhancing DOTS to meet the TB-related millennium development goals. WHO, Geneva, Switzerland 2006 (WHO/HTM/TB/2006.368).
94. Suárez PG, Floyd K, Portocarrero J et al. Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet 359(9322), 1980-1989 (2002).
95. Resch SC, Salomon JA, Murray M, Weinstein MC. Cost-effectiveness of treating multidrug-resistant tuberculosis. PLoS Med. 3(7), E241 (2006).
96. Baltussen R, Floyd K, Dye C. Cost effectiveness analysis of strategies for tuberculosis control in developing countries. BMJ 331(7529), 1364 (2005).
97. Dye C, Floyd K. Tuberculosis. Disease Control Priorities in Developing Countries (2nd Edition). Oxford, UK (2006).
98. Basu S, Galvani AP. The transmission and control of XDR TB in South Africa: an operations research and mathematical modelling approach. Epidemiol. Infect. 136(9), 1-14 (2008).
99. Espinal MA, Dye C. Can DOTS control multidrug-resistant tuberculosis? Lancet 365(9466), 1206-1209 (2005).
100. Murray CJ, Salomon JA. Expanding the WHO tuberculosis control strategy: rethinking the role of active case-finding. Int. J. Tuberc. Lung Dis. 2(9 Suppl. 1), S9-S15 (1998).
101. Bayona J, Chavez-Pachas AM, Palacios E, Llaro K, Sapag R, Becerra MC. Contact investigations as a means of detection and timely treatment of persons with infectious multidrug-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 7(12 Suppl. 3), S501-S509 (2003).
102. Becerra MC, Pachao-Torreblanca IF, Bayona J et al. Expanding tuberculosis case detection by screening household contacts. Public Health Rep. 120(3), 271-277 (2005).
103. Song B, Castillo-Chavez C, Aparicio JP. Tuberculosis models with fast and slow dynamics: the role of close and casual contacts. Math. Biosci. 180, 187-205 (2002).
104. Aparicio JP, Capurro AF, Castillo-Chavez C. Transmission and dynamics of tuberculosis on generalized households. J. Theor. Biol. 206(3), 327-341 (2000).
105. Balcells ME, Thomas SL, Godfrey-Faussett P, Grant AD. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg. Infect. Dis. 12(5), 744-751 (2006).
106. Mtei L, Matee M, Herfort O et al. High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania. Clin. Infect. Dis. 40(10), 1500-1507 (2005).
107. Matee M, Mtei L, Lounasvaara T, Wieland-Alter W et al. Sputum microscopy for the diagnosis of HIV-associated pulmonary tuberculosis in Tanzania. BMC Public Health 8, 68 (2008).
108. Cohen T, Lipsitch M, Walensky RP, Murray M. Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfected populations. Proc. Natl Acad. Sci. USA 103(18), 7042-7047 (2006).
109. Atun RA, Lebcir R, Drobniewski F, Coker RJ. Impact of an effective multidrugresistant tuberculosis control programme in the setting of an immature HIV epidemic: system dynamics simulation model. Int. J. STD AIDS 16(8), 560-570 (2005).
110. Atun RA, Lebcir RM, McKee M, Habicht J, Coker RJ. Impact of joined-up HIV harm reduction and multidrug resistant tuberculosis control programmes in Estonia: system dynamics simulation model. Health Policy 81(2-3), 207-217 (2007).
111. Dowdy DW, Chaisson RE, Maartens G, Corbett EL, Dorman SE. Impact of enhanced tuberculosis diagnosis in South Africa: a mathematical model of expanded culture and drug susceptibility testing. Proc. Natl Acad. Sci. USA 105(32), 11293-11298 (2008).
112. Barnard M, Albert H, Coetzee G, O'Brien R, Bosman ME. Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am. J. Respir. Crit. Care Med. 177(7), 787-792 (2008).
113. Moore DAJ, Evans CAW, Gilman RH et al. Microscopic-observation drug-susceptibility assay for the diagnosis of TB. N. Engl. J. Med. 355(15), 1539-1550 (2006).
114. Acuña-Villaorduña C, Vassall A, Henostroza G et al. Cost-effectiveness analysis of introduction of rapid, alternative methods to identify multidrug-resistant tuberculosis in middle-income countries. Clin. Infect. Dis. 47(4), 487-495 (2008).
115. Mitnick CD, Castro KG, Harrington M, Sacks LV, Burman W. Randomized trials to optimize treatment of multidrug-resistant tuberculosis. PLoS Med. 4(11), E292 (2007).
116. Cobelens FGJ, Heldal E, Kimerling ME et al. Scaling up programmatic management of drug-resistant tuberculosis: a prioritized research agenda. PLoS Med. 5(7), E150 (2008).
117. Spigelman M, Gillespie S. Tuberculosis drug development pipeline: progress and hope. Lancet 367(9514), 945-947 (2006).
118. Salomon JA, Lloyd-Smith JO, Getz WM et al. Prospects for advancing tuberculosis control efforts through novel therapies. PLoS Med. 3(8), E273 (2006).
119. Godfrey-Faussett P, Sonnenberg P, Shearer SC et al. Tuberculosis control and molecular epidemiology in a South African gold-mining community. Lancet 356(9235), 1066-1071 (2000).
120. Alland D, Kalkut GE, Moss AR et al. Transmission of tuberculosis in New York City. An analysis by DNA fingerprinting and conventional epidemiologic methods. N. Engl. J. Med. 330(24), 1710-1716 (1994).
121. Van Rie A, Warren R, Richardson M et al. Classification of drug-resistant tuberculosis in an epidemic area. Lancet 356(9223), 22-25 (2000).
122. Teixeira L, Perkins MD, Johnson JL et al. Infection and disease among household contacts of patients with multidrugresistant tuberculosis. Int. J. Tuberc. Lung Dis. 5(4), 321-328 (2001).
123. Jia Z-W, Jia X-W, Liu Y-X et al. Spatial analysis of tuberculosis cases in migrants and permanent residents, Beijing, 2000-2006. Emerg. Infect. Dis. 14(9), 1413-1419 (2008).